We are live on
!
Find out more
PCM
Prelude Capital Management Portfolio holdings
AUM
$1.31B
1-Year Est. Return
62.02%
This Fund
S&P 500
This Quarter
Est. Return
+31.28%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.82B
AUM Growth
+$324M
(+22%)
Cap. Flow
-$120M
Cap. Flow
% of AUM
-6.62%
Top 10 Holdings %
Top 10 Hldgs %
36.31%
Holding
2,419
New
1,036
Increased
430
Reduced
305
Closed
497
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 0-5 Year High Yield Corporate Bond ETF
SHYG
|
+$24M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$7.59M |
| 3 |
CZR
Caesars Entertainment Corporation
CZR
|
+$5.85M |
| 4 |
Broadcom
AVGO
|
+$5.1M |
| 5 |
ACIA
Acacia Communications Inc
ACIA
|
+$3.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$16.1M |
| 2 |
WBC
WABCO HOLDINGS INC.
WBC
|
+$11.4M |
| 3 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
+$11.3M |
| 4 |
Vanguard Short-Term Corporate Bond ETF
VCSH
|
+$10.3M |
| 5 |
Micron Technology
MU
|
+$8.71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.98% |
| 2 | Consumer Discretionary | 5.02% |
| 3 | Healthcare | 3.42% |
| 4 | Financials | 2.97% |
| 5 | Industrials | 2.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MNTA
451
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $537K | 0.03% |
16,144
+8,791
| +120% | +$280K |
|
452
DexCom
DXCM
$32B
| $531K | 0.03% |
+5,244
| New | +$469K |
|
453
Fate Therapeutics
FATE
$326M
| $530K | 0.03% |
+15,448
| New | +$460K |
|
454
Cardinal Health
CAH
$55.4B
| $526K | 0.03% |
10,083
+7,851
| +352% | +$405K |
|
455
Purple Innovation
PRPL
$41.7M
| $525K | 0.03% |
1,166
+1,146
| +5,730% | +$361K |
|
|
TCO
456
PUT
DELISTED
Taubman Centers Inc.
TCO
| $525K | 0.03% |
13,900
+12,900
| +1,290% | +$527K |
|
457
SandRidge Energy
SD
$503M
| $523K | 0.03% |
405,550
+4,537
| +1% | +$6.81K |
|
458
LiveRamp
RAMP
$2.3B
| $516K | 0.03% |
+12,140
| New | +$478K |
|
459
BioMarin Pharmaceuticals
BMRN
$12.4B
| $515K | 0.03% |
4,177
+1,209
| +41% | +$120K |
|
460
Berkshire Hathaway Class B
BRK.B
$1.13T
| $515K | 0.03% |
2,884
+876
| +44% | +$160K |
|
461
Trane Technologies
TT
$106B
| $515K | 0.03% |
+5,786
| New | +$503K |
|
462
CALL
Wayfair
W
$14.6B
| $514K | 0.03% |
2,600
| – | – |
|
|
SNV
463
CALL
DELISTED
Synovus
SNV
| $513K | 0.03% |
25,000
| – | – |
|
464
Eastman Chemical
EMN
$8.42B
| $508K | 0.03% |
+7,297
| New | +$460K |
|
465
Prologis
PLD
$133B
| $507K | 0.03% |
5,429
+5,155
| +1,881% | +$460K |
|
466
United Therapeutics
UTHR
$23.1B
| $506K | 0.03% |
+4,180
| New | +$470K |
|
467
Unum
UNM
$14.3B
| $503K | 0.03% |
30,312
+11,954
| +65% | +$189K |
|
|
XYZ
468
Block Inc
XYZ
$47.5B
| $500K | 0.03% |
4,766
-27,242
| -85% | -$2.09M |
|
469
PUT
Snap
SNAP
$9.01B
| $496K | 0.03% |
+21,100
| New | +$375K |
|
470
CoStar Group
CSGP
$12.3B
| $494K | 0.03% |
+6,950
| New | +$449K |
|
471
Lockheed Martin
LMT
$136B
| $482K | 0.03% |
1,322
+688
| +109% | +$260K |
|
472
iShares Core S&P 500 ETF
IVV
$904B
| $479K | 0.03% |
+1,546
| New | +$454K |
|
473
DTE Energy
DTE
$29.1B
| $476K | 0.03% |
+5,208
| New | +$461K |
|
474
PUT
United States Oil Fund
USO
$1.67B
| $474K | 0.03% |
16,900
+16,600
| +5,533% | +$454K |
|
|
PARA
475
CALL
DELISTED
Paramount Global Class B
PARA
| $473K | 0.03% |
+20,300
| New | +$391K |
|
Similar funds
PFBT
CCP
SP
HCS
SPC
GPCM
MCM
CC
Prelude Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Prelude Capital Management held 2,419 positions worth $1.82B, up 22% from $1.49B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Prelude Capital Management withdrew a net $120M in Q2 2020, closing 497 positions and reducing 305 holdings. Its most notable exit was Allergan plc, an estimated $16.1M position sold in full.
By sector, the portfolio is most concentrated in Technology at 7% of assets, up from 6.3% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Prelude Capital Management opened a new position in iShares 0-5 Year High Yield Corporate Bond ETF worth $24.4M.
- Prelude Capital Management's largest Q2 2020 buy was iShares 0-5 Year High Yield Corporate Bond ETF: 568,440 shares worth $24.4M.
- Prelude Capital Management added most to Acacia Communications Inc in Q2 2020, an estimated $3.72M increase.
- Prelude Capital Management's biggest Q2 2020 reduction was Micron Technology, cutting an estimated $8.71M.
- Prelude Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $16.1M.
- Prelude Capital Management's ten largest holdings make up 36% of its $1.82B portfolio in Q2 2020.
- Prelude Capital Management opened 1,036 new positions and closed 497 in Q2 2020.
- Prelude Capital Management's portfolio value rose 22% quarter-over-quarter to $1.82B.
Based on Prelude Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.